Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
KisqaliⓇ NATALEE unique in covering a broad population of eBC
Kisqali eBC opportunity
Multibillion USD1
Incident population (estimated)³
US
EU5
Stage II
66k
66k
Stage III
15k
24k
Stage IV (metastatic)
32k
32k
NATALEE population
Covers -70% of Stage II, 100% of Stage III
~2-3x patient opportunity vs. monarchE
eBC early breast cancer.
NATALEE covers broad population in eBC
Stage II (132k)3
NO
NO
NO
Unique to
NATALEE²
Stage III (39k)³
NO
N1
INNOVATION
Unique to
NATALEE
Total NATALEE
opportunity
N2
N1
Total NATALEE
opportunity
N3
ET endocrine therapy. iDFS invasive disease-free survival.
1. Unprobabilized peak sales.
2. Under stage II: NO, TON1 is excluded; T2N0 only if G3, or G2 with Ki67≥20% or high risk on Oncotype DX/
3. Estimated incidence US + EU5. Sources: DRG (US) and Kantar (EU5). TNM and grade information based on SEER AJCC 8th Incidence Report.
Prosigna / MammaPrint / EndoPredict.
8 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation